La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Aarti Drugs Croissance future

Future contrôle des critères 4/6

Aarti Drugs devrait augmenter ses bénéfices et ses revenus de 36.4% et de 14.7% par an respectivement, tandis que le BPA devrait croître de croître de 46.2% par an.

Informations clés

36.4%

Taux de croissance des bénéfices

46.2%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	18.1%
Taux de croissance des recettes	14.7%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	30 Jul 2024

Mises à jour récentes de la croissance future

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01

Recent updates

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Sep 05

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

May 04

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Jan 30

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

May 17

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Nov 22

We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Aug 28

Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Aug 19

Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

May 17

Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Apr 04

Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Mar 17

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02

Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07

If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Dec 23

Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Dec 08

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 23

How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Nov 08

Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)

Oct 11

Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 514% Share Price Increase Shows How Capitalism Can Build Wealth

Sep 23

Aarti Drugs Limited's (NSE:AARTIDRUGS) Business Is Trailing The Market But Its Shares Aren't

Sep 10

Prévisions de croissance des bénéfices et des revenus

NSEI:AARTIDRUGS - Estimations futures des analystes et données financières antérieures (INR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2026	31,313	2,990	1,181	N/A	1
3/31/2025	27,239	2,152	765	N/A	1
6/30/2024	24,228	1,568	N/A	N/A	N/A
3/31/2024	25,286	1,714	1,326	3,589	N/A
12/31/2023	26,510	1,802	N/A	N/A	N/A
9/30/2023	27,090	1,802	1,213	3,171	N/A
6/30/2023	27,552	1,794	N/A	N/A	N/A
3/31/2023	27,161	1,663	-315	1,333	N/A
12/31/2022	26,679	1,656	N/A	N/A	N/A
9/30/2022	26,387	1,872	-836	700	N/A
6/30/2022	25,306	1,910	N/A	N/A	N/A
3/31/2022	24,886	2,050	-816	704	N/A
12/31/2021	22,961	2,014	N/A	N/A	N/A
9/30/2021	21,916	2,111	137	1,322	N/A
6/30/2021	21,901	2,438	N/A	N/A	N/A
3/31/2021	21,548	2,804	667	1,550	N/A
12/31/2020	21,027	2,876	N/A	N/A	N/A
9/30/2020	20,459	2,474	1,338	2,070	N/A
6/30/2020	19,453	2,044	N/A	N/A	N/A
3/31/2020	18,061	1,414	2,028	2,507	N/A
12/31/2019	18,156	1,100	N/A	N/A	N/A
9/30/2019	17,222	1,031	N/A	N/A	N/A
6/30/2019	15,921	888	N/A	N/A	N/A
3/31/2019	15,609	898	688	1,431	N/A
12/31/2018	14,136	863	N/A	N/A	N/A
9/30/2018	13,689	887	N/A	N/A	N/A
6/30/2018	13,407	943	N/A	N/A	N/A
3/31/2018	12,436	823	N/A	698	N/A
12/31/2017	11,592	790	N/A	N/A	N/A
9/30/2017	11,340	735	N/A	N/A	N/A
6/30/2017	11,569	721	N/A	N/A	N/A
3/31/2017	11,952	818	N/A	1,748	N/A
12/31/2016	12,102	785	N/A	N/A	N/A
9/30/2016	11,856	776	N/A	N/A	N/A
6/30/2016	11,431	713	N/A	N/A	N/A
3/31/2016	11,349	687	N/A	1,333	N/A
12/31/2015	11,101	686	N/A	N/A	N/A
9/30/2015	11,047	744	N/A	N/A	N/A
6/30/2015	11,180	774	N/A	N/A	N/A
3/31/2015	10,943	773	N/A	1,046	N/A
12/31/2014	10,868	807	N/A	N/A	N/A
9/30/2014	10,490	721	N/A	N/A	N/A
6/30/2014	10,109	662	N/A	N/A	N/A
3/31/2014	9,699	608	N/A	954	N/A
12/31/2013	9,083	526	N/A	N/A	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de AARTIDRUGS ( 36.4% par an) est supérieure au taux d'épargne ( 6.7% ).

Bénéfices vs marché: Les bénéfices de AARTIDRUGS ( 36.4% par an) devraient croître plus rapidement que le marché Indian ( 16.9% par an).

Croissance élevée des bénéfices: Les bénéfices de AARTIDRUGS devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de AARTIDRUGS ( 14.7% par an) devrait croître plus rapidement que le marché Indian ( 10% par an).

Croissance élevée des revenus: Le chiffre d'affaires de AARTIDRUGS ( 14.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de AARTIDRUGS devrait être élevé dans 3 ans

Aarti Drugs Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 9.4% to ₹562

Price target increased by 22% to ₹578

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Price target decreased by 8.0% to ₹473

Price target decreased to ₹678

Price target decreased to ₹678

Recent updates

Aarti Drugs Limited, Annual General Meeting, Sep 20, 2024

Aarti Drugs Limited, Annual General Meeting, Sep 20, 2024

Aarti Drugs Limited (BSE:524348) announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.

Aarti Drugs Limited to Report Q1, 2025 Results on Jul 26, 2024

Full year 2024 earnings: EPS in line with expectations, revenues disappoint

High number of new directors

Aarti Drugs Limited Announces Executive Cessation

Price target decreased by 9.4% to ₹562

Upcoming dividend of ₹1.00 per share at 0.2% yield

Third quarter 2024 earnings released: EPS: ₹3.99 (vs ₹3.96 in 3Q 2023)

Aarti Drugs Limited Announces Interim Dividend for the Financial Year 2023- 24

Aarti Drugs Limited to Report Q3, 2024 Results on Jan 24, 2024

Second quarter 2024 earnings released: EPS: ₹4.29 (vs ₹4.19 in 2Q 2023)

Now 21% undervalued

Aarti Drugs Limited to Report Q2, 2024 Results on Oct 19, 2023

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Now 21% undervalued

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Aarti Drugs Limited, Annual General Meeting, Sep 26, 2023

Aarti Drugs Limited, Annual General Meeting, Sep 26, 2023

Price target increased by 22% to ₹578

Aarti Drugs Limited (BSE:524348) announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.

First quarter 2024 earnings released: EPS: ₹5.17 (vs ₹3.76 in 1Q 2023)

Aarti Drugs Limited to Report Q1, 2024 Results on Jul 21, 2023

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 17%

Upcoming dividend of ₹1.00 per share at 0.2% yield

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Price target decreased by 8.0% to ₹473

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Third quarter 2023 earnings released: EPS: ₹3.96 (vs ₹6.30 in 3Q 2022)

Aarti Drugs Limited Declares Interim Dividend for the Financial Year 2022-23

Aarti Drugs Limited to Report Q3, 2023 Results on Jan 27, 2023

Second quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.60 in 2Q 2022)

Aarti Drugs Limited to Report Q2, 2023 Results on Oct 20, 2022

Aarti Drugs Limited Appoints Independent Directors

Aarti Drugs Limited to Report Q1, 2023 Results on Jul 27, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aarti Drugs Limited, Annual General Meeting, Aug 04, 2022

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

Aarti Drugs Limited Announces Executive Appointments

Aarti Drugs Limited Announces Executive Appointments

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% undervalued after recent price drop

Price target decreased to ₹678

Less than half of directors are independent

Price target decreased to ₹678

Investor sentiment improved over the past week

Aarti Drugs Limited Announces Board Changes

Insider recently sold ₹79m worth of stock

Now 21% undervalued after recent price drop

Whole-Time Director recently bought ₹761k worth of stock

Chairman recently bought ₹4.3m worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aarti Drugs Limited to Report Q3, 2022 Results on Jan 31, 2022

Aarti Drugs Limited to Report Q3, 2022 Results on Jan 31, 2022

Now 20% undervalued after recent price drop

Chairman recently bought ₹104k worth of stock

Chairman recently bought ₹15m worth of stock

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Price target decreased to ₹780

Price target decreased to ₹780

Second quarter 2022 earnings released: EPS ₹4.60 (vs ₹8.08 in 2Q 2021)

We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Price target decreased to ₹862

First quarter 2022 earnings released: EPS ₹5.25 (vs ₹9.17 in 1Q 2021)